Roth Capital analyst Jotin Marango noted that ArQule presented clinical data on its BTK inhibitor ARQ 531 and its AKT inhibitors Miransertib and ARQ 751 at the AACR meeting this weekend and subsequently reported the outlicensing of its FGFR inhibitor derazantinib. He believes that over the last few days the company has been able monetize its "riskier and costlier program" while presenting data that build material value into its rising programs, Marango tells investors. He raised his price target on ArQule shares to $6 from $5 and keeps a Buy rating on the stock.